Bringing the Oncology Community Together

No Age Limit for Bone Marrow Transplantation

Rainer Storb, MD
Published Online: Thursday, October 10, 2013
Seattle Cancer Care AllianceDr. Rainer Storb
Rainer Storb, MD
 
Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle Cancer Care Alliance
Seattle, WASeattle Cancer Care Alliance
Age is no longer a consideration when determining whether an older patient with blood cancer is a candidate for stem cell transplantation. That was the conclusion two years ago of the first study summarizing long-term outcomes from a series of prospective clinical trials of patients age 60 or older treated with nonmyeloablative transplants, known as mini-transplants, developed at Fred Hutchinson Cancer Research Center. The findings were published November 2, 2011, in the Journal of the American Medical Association.1

On April 20, 2013, the Journal of Clinical Oncology published results with more definitive data from nearly 1100 patients that showed comorbidities contribute significantly to poorer transplant outcomes.2 The study involved patients who were enrolled in prospective multicenter clinical trials between 1997 and 2009. All were age 60 or older; all were treated with the same nonmyeloablative regimen, developed at Fred Hutch; and all had acute or chronic leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes (which can progress to acute myeloid leukemia if not treated), or myeloproliferative diseases, such as chronic myelogenous leukemia.

Both comorbidities and a higher degree of cancer aggressiveness affected survival among these older patients. For example, patients who had fewer comorbidities and less aggressive cancer had a fiveyear survival rate of 60%, while patients with more comorbidities and more aggressive cancer had a survival rate of 30%, regardless of age.

Although survival rates of 30% to 60% may seem low, these patients all would have died of their diseases within a matter of months without a transplant. The majority of patients were referred for a transplant after they had exhausted all forms of conventional therapy.

Conventional Versus Nonmyeloablative Transplants

While there is much room for improvement, particularly with regard to relapse, these results are encouraging given the poor outcomes with nontransplant treatments, especially for patients with high-risk acute myeloid leukemia, fludarabine-refractory chronic lymphocytic leukemia, or progressive lymphoma.

Nonmyeloablative transplantation was developed by researchers at Fred Hutch specifically for older and sicker patients who could not tolerate the more toxic, highdose regimens used to prepare patients for conventional transplantation.

Conventional transplants, which are generally not performed for people who are over age 60 or are medically unfit, require high doses of total body irradiation and potent chemotherapy to eliminate cancer cells. This intense treatment destroys the patient’s blood and immune system and is fatal unless the patient is rescued by an infusion of bone marrow or stem cells from a donor.

Nonmyeloablative transplants, in contrast, rely on the ability of donor immune cells to target and destroy the patient’s cancer without the need for such high doses of radiation and chemotherapy. Instead, moderate-dose radiation and chemotherapy are used to suppress, but not destroy, the patient’s immune system. This helps the body accept the donor cells, which then go to work attacking the patient’s cancer—called the graft-versus-tumor effect—and rebuilding the patient’s immune system.

Relapse Rates

In addition to survival and the impact of comorbid conditions, the 2013 study examined rates of relapse, hospitalization, acute and chronic graftversus- host disease (GVHD), and the toxicity of the treatment to internal organs. In one key finding, disease-relapse risks, not increasing age, were associated with worse outcomes. Other data showed that two-thirds of the surviving older patients who were affected by chronic GVHD had complete resolution of their symptoms and were able to discontinue immunosuppressive medications after a median time of two-and-a-half years from diagnosis. This was comparable to the results reported by previous studies on younger patients who were treated with high-dose radiation and chemotherapy. Half of the older patients never required hospitalization after transplant.

Page: 12Next Page (2) >>
Related Articles
Role of Radiation Therapy in Hodgkin Lymphoma
Panelists discuss the evolving role of radiation therapy in Hodgkin lymphoma and whether new approaches lessen the long-term toxicity traditionally associated with this treatment modality.
FDA Approves First-Line Ofatumumab for Fludarabine-Ineligble Patients With CLL
The FDA has approved ofatumumab plus chlorambucil for previously untreated patients with chronic lymphocytic leukemia who are considered inappropriate for treatment with fludarabine therapy.
Treatment Landscape for Mantle Cell Lymphoma Continues to Evolve
Lymphoma expert Andre Goy, MD, provides insight into the rapidly changing treatment landscape for patients with mantle cell lymphoma.
Hitting the Target: How Druker’s Persistence Helped Launch a New Mode of Attack
Take a prognosis of three years, multiply it by 10, and what do you get? A staggering improvement in the survival of patients with chronic myeloid leukemia (CML), and a crucial steppingstone on the road to the targeted treatment of cancer.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.